DeepMatter expects acquisition to further the integration of chemistry with digital technology
Springer Nature has completed the sale of InfoChem GmbH to DeepMatter Group plc. InfoChem produces chemical data-management and synthesis prediction software and tools, serving global pharmaceuticals and chemicals giants such as AstraZeneca and BASF.
Following the sale, Springer Nature holds a minority stake in DeepMatter. Bettina Goerner, who leads the database research group at Springer Nature, joins DeepMatter's board as a non-executive director.
Goerner said: "We are proud of the quality database and tools InfoChem has built. We look forward to maintaining a close relationship with the InfoChem team and I'd like to thank them for all their contributions to-date. InfoChem's cheminformatics software will be integrated into DeepMatter's cloud platform, accelerating the platform's development."
DeepMatter is a leader in the digitisation of chemistry. Mark Warne, CEO, said: "We are confident that [the acquisition] will allow us to accelerate towards our end-goal: integrating chemistry with digital technology, enabling a greater use of machine learning and artificial intelligence.
"The integration of InfoChem's cheminformatic capabilities into our DigitalGlassware platform will enable increased technological development, whilst the addition of the team will further enhance DeepMatter's expertise and offering."
DigitalGlassware is a software and hardware platform allowing chemistry experiments to be recorded, coded and entered into a shared data cloud.